Abstract
To outward appearances, the publication of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial has led to a monolithic backlash against the use of ezetimibe by cardiologists for the treatment of hyperlipidemia. Rather than be swayed by popular opinion, we should each put the results of ENHANCE into context and ask the questions: should I put my trust in an imaging surrogate or in low-density lipoprotein (LDL) cholesterol (LDL-C), and how do the safety and efficacy of ezetimibe compare with other nonstatin lipid-lowering agents?
| Original language | English (US) |
|---|---|
| Pages (from-to) | 288-290 |
| Number of pages | 3 |
| Journal | Clinical Cardiology |
| Volume | 31 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 2008 |
Fingerprint
Keywords
- ENHANCE trial
- Ezetimibe
- Hypercholesterolemia
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
The implications of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression trial : A return to first principles. / Musunuru, Kiran; Blumenthal, Roger S.
In: Clinical Cardiology, Vol. 31, No. 6, 06.2008, p. 288-290.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The implications of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression trial
T2 - A return to first principles
AU - Musunuru, Kiran
AU - Blumenthal, Roger S
PY - 2008/6
Y1 - 2008/6
N2 - To outward appearances, the publication of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial has led to a monolithic backlash against the use of ezetimibe by cardiologists for the treatment of hyperlipidemia. Rather than be swayed by popular opinion, we should each put the results of ENHANCE into context and ask the questions: should I put my trust in an imaging surrogate or in low-density lipoprotein (LDL) cholesterol (LDL-C), and how do the safety and efficacy of ezetimibe compare with other nonstatin lipid-lowering agents?
AB - To outward appearances, the publication of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial has led to a monolithic backlash against the use of ezetimibe by cardiologists for the treatment of hyperlipidemia. Rather than be swayed by popular opinion, we should each put the results of ENHANCE into context and ask the questions: should I put my trust in an imaging surrogate or in low-density lipoprotein (LDL) cholesterol (LDL-C), and how do the safety and efficacy of ezetimibe compare with other nonstatin lipid-lowering agents?
KW - ENHANCE trial
KW - Ezetimibe
KW - Hypercholesterolemia
UR - http://www.scopus.com/inward/record.url?scp=46949084239&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=46949084239&partnerID=8YFLogxK
U2 - 10.1002/clc.20405
DO - 10.1002/clc.20405
M3 - Article
VL - 31
SP - 288
EP - 290
JO - Clinical Cardiology
JF - Clinical Cardiology
SN - 0160-9289
IS - 6
ER -